Sansure Biotech Inc. (SHA:688289)
China · Delayed Price · Currency is CNY 18.34
+0.26 (1.44%)
At close: Mar 6, 2026
Sansure Biotech Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 226.27 | 348.17 | 1,937 | 2,243 |
Depreciation & Amortization | 149.65 | 116.9 | 89.07 | 53.94 |
Other Amortization | 20.92 | 19.87 | 8.35 | 5.01 |
Loss (Gain) From Sale of Assets | 2.36 | 0.25 | 0.31 | -2.83 |
Asset Writedown & Restructuring Costs | -5.31 | -54.88 | 21.69 | 2.42 |
Loss (Gain) From Sale of Investments | 33.7 | -253.74 | -79.24 | -81.01 |
Provision & Write-off of Bad Debts | 13.71 | 4.98 | 45.96 | 18.49 |
Other Operating Activities | -25.6 | -13.92 | 271.83 | 36.64 |
Change in Accounts Receivable | 153.01 | 376.54 | -496.51 | -304.14 |
Change in Inventory | 36.46 | -78.3 | -282.1 | -93.03 |
Change in Accounts Payable | -305.37 | -421.3 | 1,022 | 3.12 |
Change in Other Net Operating Assets | -27.17 | -42.16 | 60.85 | 3.84 |
Operating Cash Flow | 274.45 | 43.54 | 2,559 | 1,877 |
Operating Cash Flow Growth | 530.34% | -98.30% | 36.33% | -28.96% |
Capital Expenditures | -421.1 | -391.35 | -558.83 | -372.86 |
Sale of Property, Plant & Equipment | 0.25 | 0.72 | 0.01 | 15.94 |
Cash Acquisitions | -1.07 | -113 | -11.59 | - |
Divestitures | -58.28 | - | - | - |
Sale (Purchase) of Real Estate | - | - | - | 1.77 |
Investment in Securities | 363.67 | 1,791 | -642.46 | -834.95 |
Other Investing Activities | 14.61 | 110.03 | 46.13 | 77.88 |
Investing Cash Flow | -101.92 | 1,398 | -1,167 | -1,112 |
Long-Term Debt Issued | 403.13 | 18 | - | - |
Total Debt Issued | 403.13 | 18 | - | - |
Short-Term Debt Repaid | - | - | - | -55 |
Long-Term Debt Repaid | -31.29 | -23.91 | -17.18 | -6.27 |
Total Debt Repaid | -31.29 | -23.91 | -17.18 | -61.27 |
Net Debt Issued (Repaid) | 371.84 | -5.91 | -17.18 | -61.27 |
Issuance of Common Stock | 21.45 | - | - | - |
Repurchase of Common Stock | - | -122.73 | -257.41 | -200.01 |
Common Dividends Paid | -268.4 | -400.46 | -656.93 | -439.89 |
Other Financing Activities | 7.6 | 160 | 15.57 | 12.58 |
Financing Cash Flow | 132.49 | -369.11 | -915.95 | -688.59 |
Foreign Exchange Rate Adjustments | -0 | 0.34 | -10.01 | -34.25 |
Net Cash Flow | 305.01 | 1,073 | 466.24 | 42.01 |
Free Cash Flow | -146.66 | -347.81 | 2,000 | 1,504 |
Free Cash Flow Growth | - | - | 32.97% | -40.63% |
Free Cash Flow Margin | -10.06% | -34.53% | 31.01% | 33.32% |
Free Cash Flow Per Share | -0.25 | -0.59 | 3.42 | 2.56 |
Cash Interest Paid | - | - | - | 0.32 |
Cash Income Tax Paid | 112.34 | 121.48 | 493.44 | 466.25 |
Levered Free Cash Flow | -206.02 | -227.68 | 1,293 | 898.55 |
Unlevered Free Cash Flow | -194.52 | -226.17 | 1,295 | 899.06 |
Change in Working Capital | -141.26 | -124.08 | 264.17 | -398.29 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.